Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.
Frequently asked questions
What sector does Genomictree Inc. (228760) operate in?
Genomictree Inc. belongs to the Energy sector and operates in the Biotechnology industry.
What is Genomictree Inc. (228760) current stock price?
As of the latest data, Genomictree Inc. stock price is ₩13,400, with a previous close of ₩13,870. Genomictree Inc. lost -₩470 in the last trading session, representing a -3.39% loss.
What is Genomictree Inc. (228760) current market capitalization?
Genomictree Inc. market cap is approximately 328.90 billion.
Does Genomictree Inc. (228760) pay dividends?
No. Genomictree Inc. does not pay a dividend.
What is Genomictree Inc. (228760) beta (volatility) score?
Genomictree Inc. has a beta of 2.252, indicating very high volatility compared to the market.
